Business Wire

KAYTUS

23.5.2024 17:14:31 CEST | Business Wire | Press release

Share
KAYTUS Introduces KR2280V2 Server: Unmatched Versatility Across Three Platforms

KAYTUS, a leading IT infrastructure provider, unveiled the KR2280V2 2U, 2-socket flagship server at ISC High Performance 2024. This powerhouse server supports the 4th/5th Gen Intel® Xeon®, 4th Gen AMD EPYCTM, and AmpereOne® processors, offering an impressive array of storage combinations with up to 20 LFF drives, 45 SFF drives, or 24 E3.S SSDs. When upgraded with CXL modules, the KR2280V2 horizontally expands to 16 DIMMs, effortlessly meeting the demands of memory-intensive applications. Its innovative front I/O configuration delivers remarkable scalability, supporting up to 20 PCIe 5.0 devices, setting a new benchmark in performance. With its flexible compute capabilities and adaptable storage and I/O designs, the KR2280V2 is engineered to accommodate a wide spectrum of business needs— ranging from general computing to accelerated computing, and from massive storage capacity to high-performance I/O-oriented applications. This versatility makes it the ultimate solution for diverse application scenarios, ensuring consistent and efficient operation and maintenance.

Revolutionizing Diverse Applications Scenarios with Versatile Compute Power

To deliver the best computing solutions for diverse scenarios, the IT architecture of data centers is rapidly evolving and becoming increasingly sophisticated. As business needs diversify, a single chip can no longer meet the demands of complex, high-efficiency computing, leading to the emergence of various acceleration chips. This rapid evolution places new demands on processors' energy efficiency and core performance. The KR2280V2 boldly rises to this challenge by supporting three major computing platforms: Intel® Xeon®, AMD EPYC™, and AmpereOne®. This versatility offers a wide range of computing power options, perfectly tailored for different scenarios. By unifying management interfaces, the KR2280V2 dramatically reduces operation and maintenance pressure in heterogeneous computing configurations, making it exceptionally user-friendly and efficient.

Unparalleled Configuration Flexibility Optimized for Peak Application Performance

Through highly advanced modularization, KR2280V2 enables dynamic configurations of storage, I/O, and acceleration modules, offering an impressive array of over 100 configurations. This versatility seamlessly adapts to various scenarios, from general computing to cutting-edge heterogeneous computing, from storage-intensive to blazing-fast I/O-intensive applications, and from traditional rear I/O maintenance to innovative front I/O maintenance design. When it comes to energy efficiency, the KR2280V2 leads the way with its fully compatible cold-plated liquid cooling design, enhanced with state-of-the-art leakage detection mechanisms and bolstered system reliability.

Industry's First to Achieve BSI Cryptographic Uncompromising Security Encryption

The cryptographic module employed in KR2280V2's BMC out-of-band management module establishes a new security benchmark. It adheres fully to the stringent ISO/IEC 19790:2012 requirements, delivering excellence across role permissions, service and authentication, software/firmware security, operating environment security, and full-process self-inspection. Simultaneously, it ensures an end-to-end security system through the integration of state-of-the-art technologies. From dual flash chips to BMC self-recovery mechanisms, comprehensive access control, and multiple authentications, every aspect is meticulously designed to safeguard critical business data with uncompromising encryption. The KR2280V2 sets the standard for data security in the digital age.

About KAYTUS

KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523414563/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 15:22:00 CEST | Press release

Healthcare and life sciences leaders are advancing AI with caution—fragmentation, capability gaps, and execution challenges are slowing enterprise-wide impact AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design a

JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 15:00:00 CEST | Press release

International Olympic Committee and JPMorganChase Announce Landmark Global Olympic Partnership The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support t

BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 15:00:00 CEST | Press release

BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release

Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release

CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye